(Q38136837)

29 August 2017

Local or systemic treatment for New World cutaneous leishmaniasis? Re-evaluating the evidence for the risk of mucosal leishmaniasis (English)

1 reference

29 August 2017

3

1 reference

29 August 2017

6

Eric Caumes

0 references

Jan Clerinx

7

object named as

Jan Clerinx

1 reference

29 August 2017

10

Christoph Hatz

1 reference

29 August 2017

2

Diana N J Lockwood

1 reference

29 August 2017

Johannes Blum

1

1 reference

29 August 2017

Gundel Harms

4

1 reference

29 August 2017

Mark S Bailey

5

1 reference

29 August 2017

Eric Caumes

6

1 reference

29 August 2017

Pieter P A M van Thiel

8

1 reference

29 August 2017

Gloria Morizot

9

1 reference

29 August 2017

Pierre Buffet

11

1 reference

29 August 2017

1 September 2012

1 reference

29 August 2017

1 reference

29 August 2017

4

1 reference

29 August 2017

3

1 reference

29 August 2017

153-163

1 reference

[Diagnosis and therapy of cutaneous and mucocutaneous Leishmaniasis in Germany].

29 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Treatment of cutaneous leishmaniasis among travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

New world cutaneous leishmaniasis in travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Treatment of cutaneous leishmaniasis in travelers 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

New World cutaneous leishmaniasis: updated review of current and future diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Current diagnosis and treatment of cutaneous and mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

The efficacy of treatment with intralesional meglumine antimoniate alone, compared with that of cryotherapy combined with the meglumine antimoniate or intralesional sodium stibogluconate, in the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Comparative study of the efficacy of combined cryotherapy and intralesional meglumine antimoniate (Glucantime) vs. cryotherapy and intralesional meglumine antimoniate (Glucantime) alone for the treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Topical treatment of Old World cutaneous leishmaniasis caused by Leishmania major: A double-blind control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Topical treatment of American cutaneous leishmaniasis with paramomycin and methylbenzethonium chloride: a clinical study under field conditions in Ecuador

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Eco-epidemiological survey of Leishmania (Viannia) braziliensis American cutaneous and mucocutaneous leishmaniasis in Ribeira Valley River, Paraná State, Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Epidemiological studies of an outbreak of cutaneous leishmaniasis in the Rio Jequitinhonha Valley, Minas Gerais, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

The epidemiology and control of leishmaniasis in Andean countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Fifteen years of cutaneous and mucocutaneous leishmaniasis in Bolivia: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal leishmaniasis ("espundia" Escomel, 1911).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Changing epidemiology of American cutaneous leishmaniasis (ACL) in Brazil: a disease of the urban-rural interface

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal leishmaniasis: epidemiological and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Successful diagnosis and treatment 50 years after exposure: is mucocutaneous leishmaniasis still a neglected differential diagnosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Molecular epidemiology of American tegumentary leishmaniasis in Panama.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Placebo-Controlled Clinical Trial of Sodium Stibogluconate (Pentostam) versus Ketoconazole for Treating Cutaneous Leishmaniasis in Guatemala

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal leishmaniasis ("espundia") responsive to low dose of N-methyl glucamine (Glucantime) in Rio de Janeiro, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Clinical presentations of Leishmania braziliensis braziliensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

New world mucosal and cutaneous leishmaniasis: an emerging health problem among British travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Mucosal leishmaniasis . Current scenario and prospects for treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Successful treatment of cutaneous leishmaniasis with lipid formulations of amphotericin B in two immunocompromised patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Imported leishmaniasis: a heterogeneous group of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

American tegumentary leishmaniasis (ATL) in Rio de Janeiro State, Brazil: main clinical and epidemiologic characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Cutaneous leishmaniasis associated with extensive lymphadenopathy during an epidemic in Ceará State, northeast Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Detection of Leishmania in unaffected mucosal tissues of patients with cutaneous leishmaniasis caused by Leishmania (Viannia) species.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Leishmaniasis among organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Endemic tegumentary leishmaniasis in Brazil: correlation between level of endemicity and number of cases of mucosal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Clinical features of cutaneous and disseminated cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis in Paraty, Rio de Janeiro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Cutaneous leishmaniasis in British troops following jungle training in Belize

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Increase of imported Leishmaniasis in the Netherlands: a twelve year overview (1996-2007).

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Cutaneous leishmaniasis: review of 59 cases seen at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

American cutaneous leishmaniasis in U.S. travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Localized cutaneous leishmaniasis imported into Paris: a review of 39 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Cutaneous leishmaniasis in three Dutch military cohorts following jungle training in Belize

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

21 January 2018

Leishmaniasis in Germany

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Changing pattern of imported cutaneous leishmaniasis in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Leishmaniasis, an emerging imported infection: report of 20 cases from Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Experience with New World cutaneous leishmaniasis in travelers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Systematic review of the adverse effects of cutaneous leishmaniasis treatment in the New World.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Electrocardiographic and biochemical adverse effects of sodium stibogluconate during treatment of cutaneous and mucosal leishmaniasis among returned travellers

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Thrombocytopenia complicating sodium stibogluconate therapy for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Herpes zoster and lymphopenia associated with sodium stibogluconate therapy for cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Pentamidine, the drug of choice for the treatment of cutaneous leishmaniasis in Surinam

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Rhabdomyolysis associated with pentamidine isethionate therapy for American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Influence of clinical presentation on the efficacy of a short course of pentamidine in the treatment of cutaneous leishmaniasis in French Guiana

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Oral miltefosine for the treatment of Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Efficacy of miltefosine for the treatment of American cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Miltefosine treatment of Leishmania major infection: an observational study involving Dutch military personnel returning from northern Afghanistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Randomized controlled clinical trial to access efficacy and safety of miltefosine in the treatment of cutaneous leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, Brazil

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Treatment of New World cutaneous leishmaniasis with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Lipsosomal amphotericin B for treatment of cutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Traitement des leishmanioses en France : proposition d’un référentiel consensuel

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

Oral leishmaniasis: a clinicopathological study of 11 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.INHE.2012.06.004

10.1016/J.INHE.2012.06.004

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference